AbbVie Inc (ABBV)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
ZJYL
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
$2.17
-1.81%
HEALTHCARE · Cap: $18.00M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 295540% more annual revenue ($61.16B vs $20.69M). ABBV leads profitability with a 6.9% profit margin vs 5.8%. ZJYL trades at a lower P/E of 11.5x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ZJYL
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for ZJYL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 4.8% — below average capital efficiency
5.8% margin — thin
Revenue declined 16.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ZJYL
The strongest argument for ZJYL centers on P/E Ratio, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ZJYL
The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin.
Key Dynamics to Monitor
ZJYL carries more volatility with a beta of 9.37 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?